24.06.2015 - CVC and Temasek to buy Alvogen
A consortium of investors led by CVC Capital Partners, and including Singapore-based sovereign wealth fund Temasek and Vatera Healthcare Partners,acquired a controlling stake in Alvogen, the US pharmaceutical company. The bilateral deal values the privately held company at $2bn (£1.3bn), including debt. The shares come from Pamplona Capital Management’s stake, and the investment managers will retain a small interest. This is the latest pharma deal in a global trend which has seen $250bn worth of pharmaceutical mergers and acquisitions so far this year...............................................Full Article: Source
Print